AstraZeneca’s Imfinzi/treme combo strikes out — again — in lung cancer. Is it time for last rites?
AstraZeneca bet big on the future of their PD-L1 Imfinzi combined with the experimental CTLA-4 drug tremelimumab. But once again it’s gone down to defeat in a major Phase III study — while adding damage to the theory involving targeting cancer with a high tumor mutational burden.
Early Wednesday the pharma giant announced that their NEPTUNE study had failed, with the combination unable to beat standard chemo at overall survival in high TMB cases of advanced non-small cell lung cancer. We won’t get hard data until later in the year, but the drumbeat of failures will call into question what — if any — future this combination can have left.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 73,300+ biopharma pros reading Endpoints daily — and it's free.